Fig. 1. Schematic illustration of RILO@MG promoting specific tumour phagocytosis and generating drug exosomes that play a role in triggering an antitumour immune response to combat solid tumour.
a Preparation of RILO@MG. First, RILO@M was prepared by the inner packing of M1-type macrophages and RILO. Then, DSPE-PEG5k-GTP was anchored on the surface of RILO@M to prepare RILO@MG. b RILO@MG accumulated in the tumour site through chemotaxis and GPC3-mediated targeting after i.v. administration directly killed tumour cells by GPC3-mediated phagocytosis and generated RI-exosomes containing R848 and INCB to regulate the TAM phenotype and enhance T-cell viability. Therefore, RILO@MG exerted antitumour efficacy by directly killing tumour cells and reversing the suppressive TME. CTL cytotoxic T-cell.